Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, Endpoints News reports

() -Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter. The agreement can be announced this week, the report added.